Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) EBIT Margin: 2017-2025

Historic EBIT Margin for Aclaris Therapeutics (ACRS) over the last 8 years, with Sep 2025 value amounting to -519.82%.

  • Aclaris Therapeutics' EBIT Margin fell 27889.00% to -519.82% in Q3 2025 from the same period last year, while for Sep 2025 it was -973.93%, marking a year-over-year decrease of 80294.00%. This contributed to the annual value of -758.18% for FY2024, which is 44663.00% down from last year.
  • Aclaris Therapeutics' EBIT Margin amounted to -519.82% in Q3 2025, which was up 49.82% from -1,035.90% recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year EBIT Margin high stood at -23.03% for Q4 2023, and its period low was -1,702.25% during Q2 2023.
  • Moreover, its 3-year median value for EBIT Margin was -789.45% (2024), whereas its average is -784.07%.
  • Examining YoY changes over the last 5 years, Aclaris Therapeutics' EBIT Margin showed a top increase of 123,753bps in 2024 and a maximum decrease of 105,910bps in 2024.
  • Quarterly analysis of 5 years shows Aclaris Therapeutics' EBIT Margin stood at -1,525.18% in 2021, then spiked by 115,012bps to -375.07% in 2022, then skyrocketed by 35,203bps to -23.03% in 2023, then tumbled by 105,910bps to -1,082.13% in 2024, then slumped by 27,889bps to -519.82% in 2025.
  • Its last three reported values are -519.82% in Q3 2025, -1,035.90% for Q2 2025, and -1,242.89% during Q1 2025.